The British Medical Instruments Company was found in the basement of a pawnshop in the U.K. on Black Friday, a move that was likely prompted by the sales of the $2.9 million medical instruments.
The company’s U.S. parent, Royal Philips, announced Friday that it had sold its medical equipment business to a private equity firm that bought it in 2012.
The U.N. General Assembly approved the sale on Monday.
The sale is the latest in a series of moves by British companies to reduce their dependence on the U,S.
market for medical devices, especially since the Brexit vote.
The British government said last week it would allow private companies to bid for new licences to make medical devices.
The Royal Philips-owned company, which had its U.KS. business frozen in 2015 after a string of health problems, was among several medical device companies that closed down or moved their business to China.
The Associated Press previously reported that the Royal Philips unit had also been in talks to sell its business to an Australian firm.
The move comes amid growing concern that the U and U.E. could be forced to join the World Trade Organization, which would be a huge blow for the U., the world’s largest economy, which is in the midst of a recession.
The World Trade Organisation is expected to approve the Trans-Pacific Partnership, a deal between the U-S.
and 12 Pacific Rim countries that includes the U of A and other U.k. medical device makers.
The agreement would make the U.-U.S.-China trade pact the most heavily regulated in the world, including requirements for medicines, diagnostics and other products.
The deal is also likely to be the subject of a U.s. court challenge that could force the U to impose a tariff on U. of A-made products.
“The Royal Philips medical device division was a major player in the development of the medical device industry in the UK, the United Kingdom and the United States and has contributed to the growth of the industry and the UK’s economic recovery,” a Royal Philips spokesperson said in a statement.
“As a private company, we will not comment further on any potential future sales or investments.”